Zacks Investment Research downgraded Baxter International Inc (NYSE:BAX) to Hold in a report released today.
- Updated: October 6, 2016
Just yesterday Baxter International Inc (NYSE:BAX) traded 0.14% higher at $48.00. Baxter International Inc’s 50-day moving average is $47.05 and its 200-day moving average is $45.28. The last stock price is up 5.98% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 904,407 shares of the stock were exchanged, down from an average trading volume of 3,768,300
Zacks Investment Research has downgraded Baxter International Inc (NYSE:BAX) to Hold in a report released on Thursday October 06, 2016.
Previously on 09/15/2016, Barclays Capital released a statement about Baxter International Inc (NYSE:BAX) increased the target price from $0.00 to $52.00. At the time, this indicated a possible upside of 0.14%.
See Chart Below
Baxter International Inc has a price-earnings ratio of 5.51 with a one year low of $32.62 and a one year high of $49.49 BAX’s total market value is presently $0.
A total of 11 equity analysts have released a ratings update on BAX. zero equity analysts rating the company a strong buy, three equity analysts rating the company a buy, eleven equity analysts rating the company a hold, one equity analyst rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $48.82.
Brief Synopsis About Baxter International Inc (NYSE:BAX)
Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.